.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Fuji
US Army
Argus Health
Deloitte
Queensland Health
QuintilesIMS
Citi
Federal Trade Commission
Cipla

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,181,257

« Back to Dashboard

Which drugs does patent 9,181,257 protect, and when does it expire?


Patent 9,181,257 protects IMBRUVICA and is included in one NDA.

This patent has one hundred and fourteen patent family members in twenty-six countries.

Summary for Patent: 9,181,257

Title:Inhibitors of Bruton's tyrosine kinase
Abstract: Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: PHARMACYCLICS LLC (Sunnyvale, CA)
Application Number:14/080,640
Patent Claim Types:
see list of patent claims
Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,181,257

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,556,182Inhibitors of Bruton's tyrosine kinase► Subscribe
8,748,439Inhibitors of Bruton's tyrosine kinase► Subscribe
9,409,911Inhibitors of bruton's tyrosine kinase► Subscribe
8,399,470Inhibitors of bruton's tyrosine kinase► Subscribe
8,691,546Inhibitors of Bruton's tyrosine kinase► Subscribe
9,079,908Inhibitors of Bruton'S tyrosine kinase► Subscribe
9,133,202Inhibitors of Bruton's tyrosine kinase► Subscribe
8,741,908Inhibitors of bruton's tyrosine kinase► Subscribe
8,754,091Inhibitors of bruton's tyrosine kinase► Subscribe
9,181,263Inhibitors of bruton's tyrosine kinase► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,181,257

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2010504324► Subscribe
Denmark2081435► Subscribe
Denmark2201840► Subscribe
Denmark2526771► Subscribe
Denmark2526933► Subscribe
Denmark2526934► Subscribe
Denmark2529621► Subscribe
Eurasian Patent Organization200901313► Subscribe
Eurasian Patent Organization017865► Subscribe
Eurasian Patent Organization200900351► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Julphar
Fish and Richardson
Cerilliant
Chinese Patent Office
McKesson
Cantor Fitzgerald
Cipla
Accenture
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot